Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

17-02-2021 | ASCO GU 2021 | Conference coverage | Video

Metastatic urothelial cancer: clinical insights into trial data

Speakers: Shilpa Gupta and Petros Grivas

Shilpa Gupta and Petros Grivas share their thoughts on the key practicing-changing trials in metastatic urothelial cancer, including EV-301, EV-201, TITAN-TCC, and TROPiCS-04, and discuss the emerging role of antibody–drug conjugates in the evolving treatment landscape (16:47).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

12-02-2021 | ASCO GU 2021 | Conference coverage | Video

EV-301: Enfortumab vedotin boosts advanced urothelial cancer survival

14-02-2021 | ASCO GU 2021 | Conference coverage | Video

EV-201: Enfortumab an option for cisplatin-ineligible advanced UC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits